Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions
- 23 May 2022
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 45 (6) , 601-621
Abstract
Among the potential adverse effects of breast cancer treatment, chemotherapy-related cognitive impairment (CRCI) has gained increased attention in the past years. In this review, we provide an overview of the literature regarding CRCI in breast cancer, focusing on three main aspects. The first aspect relates to the molecular mechanisms linking individual drugs commonly used to treat breast cancer and CRCI, which include oxidative stress and inflammation, reduced neurogenesis, reduced levels of specific neurotransmitters, alterations in neuronal dendrites and spines, and impairment in myelin production. The second aspect is related to the clinical characteristics of CRCI in patients with breast cancer treated with different drug combinations. Data suggest the incidence rates of CRCI in breast cancer vary considerably, and may affect more than 50% of treated patients. Both chemotherapy regimens with or without anthracyclines have been associated with CRCI manifestations. While cross-sectional studies suggest the presence of symptoms up to 20 years after treatment, longitudinal studies confirm cognitive impairments lasting for at most 4 years after the end of chemotherapy. The third and final aspect is related to possible therapeutic interventions. Although there is still no standard of care to treat CRCI, several pharmacological and non-pharmacological approaches have shown interesting results. In summary, even if cognitive impairments derived from chemotherapy resolve with time, awareness of CRCI is crucial to provide patients with a better understanding of the syndrome and to offer them the best care directed at improving quality of life.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (150654/2020-0, 305343/2019-0)
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (18.2551.0000513-4)
This publication has 245 references indexed in Scilit:
- The impact of cancer therapy on cognition in the elderlyFrontiers in Pharmacology, 2013
- Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapyHuman Brain Mapping, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Preserved learning and memory following 5-fluorouracil and cyclophosphamide treatment in ratsPharmacology Biochemistry and Behavior, 2011
- Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment researchSupportive Care in Cancer, 2011
- Doxorubicin-induced central nervous system toxicity and protection by xanthone derivative of Garcinia MangostanaNeuroscience, 2011
- Crosstalk of reactive oxygen species and NF-κB signalingCell Research, 2010
- Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- The effect of modafinil on cognitive function in breast cancer survivorsCancer, 2009
- Cognitive‐behavioral management of chemotherapy‐related cognitive changePsycho-Oncology, 2006